Supplementary materials: Cost–effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma

These are peer-reviewed supplementary materials for the article 'Cost–effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma' published in the Journal of Comparative Effectiveness Research.Table A1: Clinical Inputs.Table A2: Cost Inputs.Table A3: Resource utilization.Table A4: Utility inputs.Aim: To assess the cost–effectiveness of brentuximab vedotin (BV) versus physician’s choice (methotrexate or bexarotene) for treating advanced cutaneous T-cell lymphoma. Materials & methods: A partitioned survival model was developed from the National Health Service perspective in England and Wales. Model inputs were informed by the ALCANZA trial, real-world UK data, published literature or clinical experts. Results: Over the modeled lifetime, BV dominated physician’s choice and provided an additional 1.58 life-years and 1.09 higher quality-adjusted life years with a net cost saving of £119,565. The net monetary benefit was £152,326 using a willingness-to-pay threshold of £30,000/quality-adjusted life year. Results were robust in sensitivity and scenario analyses. Conclusion: BV is a highly cost-effective treatment for advanced cutaneous T-cell lymphoma.

本数据集为发表于《比较疗效研究杂志》的论文《布瑞坦昔单抗维德奥宾治疗皮肤T细胞淋巴瘤的成本效益分析》的同行评审补充材料。表A1：临床输入。表A2：成本输入。表A3：资源利用。表A4：效用输入。研究目的：评估布瑞坦昔单抗（BV）与医师选择（甲氨蝶呤或贝沙罗汀）治疗晚期皮肤T细胞淋巴瘤的成本效益。研究方法：从英国及威尔士国家卫生服务体系的角度，构建了一个分割生存模型。模型输入数据来源于ALCANZA临床试验、实际英国数据、已发表文献或临床专家。研究结果：在模型模拟的整个寿命期内，BV优于医师选择，额外提供了1.58年的生命年限和1.09年的质量调整生命年限，同时实现净成本节约119,565英镑。以每质量调整生命年30,000英镑的支付意愿阈值为标准，净货币收益为152,326英镑。结果在灵敏度和情景分析中均表现稳健。研究结论：BV是治疗晚期皮肤T细胞淋巴瘤的一种高度经济有效的治疗方案。